Figure 6. Association miR-15a/16 with DMARDs treatment response in RA patients. (A, B) Expression of miR-15a (A) and miR-16 (B) in serum from RA patients (n = 32) at baseline and after 3 months DMARDs therapy. (C, D) RA patients were divided RA into responders and non-responders based on whether their DAS28 score was changed ≥ 1.2 after 3 months DMARDs therapy. Graphs show the serum levels of miR-15a (C) and miR-16 (D) in serum from responders (n = 18) and non-responders (n=14). (E, F) Changes of the serum levels miR-15a (E) and miR-16 (F) in responders (left) and non-responders (right) from baseline to after 3 months DMARDs therapy. Values are the mean ± SD.